Filing Flows › Krystal Biotech (KRYS) › Q1 2026
Krystal Biotech (KRYS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
Krystal Biotech (KRYS) reported revenue of $116M for the first quarter 2026 (Q1 2026), +32% from a year earlier and +9% from the quarter before. Operating margin was 46.1%, net earnings $55.9M (48.1% of revenue).
Krystal Biotech, Q1 2026: revenue $116M (+32% year over year), operating margin 46.1%, net earnings $55.9M, operating cash flow $80.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $116M | +9% | +32% |
| Operating profit | $53.7M | +21% | +48% |
| Net earnings | $55.9M | +9% | +57% |
| Operating cash flow | $80.4M | +4% | +160% |
| Free cash flow | $73.2M | -3% | +196% |
What changed
Revenue was $116.4M in Q1 2026, up 32% year over year and up 9% from the previous quarter.
Operating profit was $53.7M, a 46.1% margin (up 5.0 points year over year). Of the extra revenue versus Q1 2025, 62% reached operating profit, above the 41% margin then. Total costs grew 21% against revenue growth of 32%. The fastest-growing cost line was Other operating costs (+26%). Net earnings were $55.9M, up 57% year over year. The effective tax rate was 9.0%.
Operating cash flow was $80.4M (up 160% year over year), 144% of net earnings. Non-cash charges added back $1.5M of depreciation and $13.6M of share-based compensation. Working capital and other items added $9.3M. Capital expenditures of $7.1M left free cash flow of $73.2M.
Questions
What was Krystal Biotech's revenue in the first quarter 2026?
Krystal Biotech (KRYS) reported revenue of $116M for the first quarter 2026 (Q1 2026), +32% from a year earlier and +9% from the quarter before.
Was Krystal Biotech profitable in the first quarter 2026?
Operating profit was $53.7M (46.1% of revenue) and net earnings $55.9M.
Source: Krystal Biotech 10-Q on SEC EDGAR.